Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

已完结 10 由 Semaglutide 发布于 2026/6/2 8:52:40

DOI:10.1016/s0140-6736(26)00202-3
作者：Julio Rosenstock, Daisuke Yabe, David Cox, Jianghao Li, Max Denning, Wen-Shuo Wu, Rong Liu, Youna Zhao
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundOrforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral administration without food or water restrictions. This study aimed to compare the efficacy and

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Chalcone-Terpene Hybrids from <i>Fissistigma litseifolium</i> (King) Merr as Potential Carbapenemase Inhibitors.